PANACEABIO
Panacea Biotec
Each stock's 10,000-path forecast, rendered as light.
Panacea Biotec (PANACEABIO) Stock Analysis & Case Study
Is PANACEABIO a good buy? The data-driven verdict.
on the numbers it mixed signals, a Downstox Snapshot Score of 53/100.
On the numbers, Panacea Biotec (PANACEABIO) mixed signals, a Downstox Snapshot Score of 53/100, weighing a 81% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
PANACEABIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of PANACEABIO history (71%/yr drift, 60%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| PANACEABIO 2027 | ₹423 | ₹911 | ₹1,933 | +70% |
| PANACEABIO 2028 | ₹531 | ₹1,554 | ₹4,589 | +190% |
| PANACEABIO 2029 | ₹699 | ₹2,621 | ₹9,833 | +389% |
| PANACEABIO 2030 | ₹957 | ₹4,467 | ₹19,876 | +733% |
| PANACEABIO 2031 | ₹1,387 | ₹7,653 | ₹39,783 | +1327% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability PANACEABIO goes up, or doubles?
The bull case for PANACEABIO
- A 10,000-path probability model puts a 81% chance the price is higher in a year, with a median target of ₹911 (+70%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹9,833.
The bear case & risks
- High historical volatility (60%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹699.
PANACEABIO volatility & expected range, how bumpy is the ride?
Over the last 2.0 years PANACEABIO compounded at 71%/year with annualized volatility of 60%. That volatility implies a 1-year 80% range of ₹423–₹1,933, the honest backbone behind any single price target.
PANACEABIO price forecast, the full 60-month probability fan
PANACEABIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds PANACEABIO hits common targets within the simulated horizon?
Full multi-horizon detail on the PANACEABIO price target & forecast page.
PANACEABIO MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy PANACEABIO with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 42.2% | 2.4× |
| ZerodhaCHEAPEST | 42.2% | 2.4× |
| Dhan | 50.0% | 2.0× |
Compare every broker on the PANACEABIO MTF page.
PANACEABIO vs peers,sector comparison
About Panacea Biotec: sector, index & market-cap context
Panacea Biotec (PANACEABIO) is an NSE-listed company.
How the PANACEABIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Panacea Biotec's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
PANACEABIO analysis, FAQs
Is Panacea Biotec (PANACEABIO) a good buy?
On the numbers, Panacea Biotec (PANACEABIO) mixed signals, a Downstox Snapshot Score of 53/100, weighing a 81% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is PANACEABIO overvalued or undervalued?
Valuation ratios for PANACEABIO are tracked live on Downstox.
What is the PANACEABIO share price target for 2031?
PANACEABIO's probability-weighted 2031 median target is ₹7,653, with an 80% range of ₹1,387–₹39,783 (10,000-path Monte-Carlo).
What is the probability PANACEABIO doubles in 5 years?
The modelled probability of PANACEABIO reaching ₹1,073 (2×) within 5 years is 93%.
What is the bull case for PANACEABIO?
A 10,000-path probability model puts a 81% chance the price is higher in a year, with a median target of ₹911 (+70%).
What are the risks in PANACEABIO?
High historical volatility (60%/yr) means a wide, bumpy range of outcomes, size positions accordingly.